Anxiety treatment
IntelliCare app suite field trial
Open access · cc by · source: Europe PMC
Eight weeks of IntelliCare apps plus light coaching produced large pre–post drops in depression and anxiety symptoms.
Study at a glance
- Design
- Human experiment — Single-arm 8-week field trial of IntelliCare Android suite with low-intensity coaching
- N
- N=105 · PHQ-9 ≥10 and/or GAD-7 ≥8 at enrollment
- Population
- Adults with elevated depression and/or anxiety symptoms
- Outcome
- PHQ-9 and GAD-7 change over 8 weeks
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Among participants with paired outcomes, PHQ-9 and GAD-7 improved significantly. By end of treatment many met remission or mild-symptom ranges (e.g., 37% PHQ-9 <5; 42% GAD-7 <5). Authors argue modular, eclectic apps can deliver scalable skills-based care.
Methodology
105 adults with PHQ-9 ≥10 and/or GAD-7 ≥8 enrolled in a single-arm field trial of the elemental IntelliCare Android suite with low-intensity coaching for 8 weeks. Usability and symptom outcomes were assessed repeatedly.
Limitations
No control group, so expectancy and concurrent care could drive change. Android-only recruitment and coaching support limit generalizability to fully self-guided public app stores.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Multiple studies in this library examine anxiety treatment with empirical patient or population outcomes rather than opinion alone.
Evidence for the claim as stated.
Among participants with paired outcomes, PHQ-9 and GAD-7 improved significantly. By end of treatment many met remission or mild-symptom ranges (e.g., 37% PHQ-9 <5; 42% GAD-7 <5). Authors argue modular, eclectic apps can deliver scalable skills-based care.
Evidence for the claim as stated.
Effect sizes and settings differ across anxiety treatment studies — digital vs clinic, trial vs observational — so results should not be pooled casually.
Evidence for the claim as stated.
Single-arm and exploratory mixed-model papers describe trajectories without a randomised comparator. Among 105 IntelliCare users enrolled at PHQ-9 ≥10 and/or GAD-7 ≥8, paired outcomes improved and 37% reached PHQ-9 <5 and 42% GAD-7 <5 by end of treatment. Among 42 cancer survivors in a Fitbit subsample, mean wear was 6.2 of 7 days weekly and intervention MVPA rose from 93.8 to 195.3 min/week — use patterns, not a Fitbit-only causal test.
Evidence for the claim as stated.
A mixed model with a randomised control (MoodGYM, Kokoro-app, Facebook walking, Glucose Buddy) answers a different question from a mixed model of change inside one arm (IntelliCare field trial, Fitbit wear). Significant PHQ-9/GAD-7 improvement to 37%/42% below 5, or MVPA doubling from 93.8 to 195.3 min/week, can be expectancy, concurrent care, or the surrounding activity trial. Those papers do not licence the same causal sentence as a 2.5-point randomised PHQ-9 gap.
Evidence for the claim as stated.
IntelliCare used PHQ-9 both to enter and to judge outcome. A single-arm field trial of 105 adults (PHQ-9 ≥10 and/or GAD-7 ≥8) found significant paired-score improvement, with 37% reaching PHQ-9 <5 and 42% GAD-7 <5 by end of treatment. A later 2×2 factorial RCT found PHQ-9 and GAD-7 fell across arms; coaching produced larger GAD-7 reductions than self-guided care, while weekly recommendations strengthened PHQ-9 gains and raised median sessions (median 216; last use day 56). Coaching did not clearly beat self-guidance on depression.
Evidence for the claim as stated.
Mean PHQ-9 change, response, remission and 'score <5' are different claims. Kokoro-app's 2.5-point ITT advantage came without a significant remission difference. IntelliCare's uncontrolled 37% below 5 is a threshold count, not a randomised remission rate. iCBT's 51% versus 18% is reliable improvement among completers with data, not the same as g=0.78 on the full ITT sample. Treating those percentages as one 'PHQ-9 worked' statistic collapses the disagreements the papers actually report.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Effect sizes and settings differ across anxiety treatment studies — digital vs clinic, trial vs observational — so results should not be pooled casually.
- Supports · Coaching vs recommendations in IntelliCare
- Supports · Automated e-therapy for anxiety disorders
A mixed model with a randomised control (MoodGYM, Kokoro-app, Facebook walking, Glucose Buddy) answers a different question from a mixed model of change inside one arm (IntelliCare field trial, Fitbit wear). Significant PHQ-9/GAD-7 improvement to 37%/42% below 5, or MVPA doubling from 93.8 to 195.3 min/week, can be expectancy, concurrent care, or the surrounding activity trial. Those papers do not licence the same causal sentence as a 2.5-point randomised PHQ-9 gap.
- Supports · MoodGYM improves population wellbeing
- Supports · Can a CBT phone app help stubborn depression?
- Supports · Fitbit wear during an activity trial
Mean PHQ-9 change, response, remission and 'score <5' are different claims. Kokoro-app's 2.5-point ITT advantage came without a significant remission difference. IntelliCare's uncontrolled 37% below 5 is a threshold count, not a randomised remission rate. iCBT's 51% versus 18% is reliable improvement among completers with data, not the same as g=0.78 on the full ITT sample. Treating those percentages as one 'PHQ-9 worked' statistic collapses the disagreements the papers actually report.
- Supports · Can a CBT phone app help stubborn depression?
- Supports · iCBT for depression in diabetes
Related papers in this topic
Same topic cluster — not a recommendation engine.